Naiyer A Rizvi

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer
    Naiyer A Rizvi
    Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Clin Oncol 20:3522-32. 2002
  2. pmc Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
    Naiyer A Rizvi
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 17:3500-6. 2011
  3. ncbi request reprint A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer
    Naiyer A Rizvi
    Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Clin Cancer Res 10:1963-70. 2004
  4. doi request reprint Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer
    Naiyer A Rizvi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:639-43. 2008
  5. pmc A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
    Paul K Paik
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lung Cancer 74:481-5. 2011
  6. pmc Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10022, USA
    J Clin Oncol 27:264-70. 2009
  7. ncbi request reprint Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 13:5150-5. 2007
  8. doi request reprint Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer
    Katharine A Price
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York City, New York, USA
    J Thorac Oncol 5:1623-9. 2010
  9. doi request reprint A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1435-7. 2011
  10. pmc A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
    Paul K Paik
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, H1011, New York, NY 10065, USA
    Cancer Chemother Pharmacol 68:1331-7. 2011

Research Grants

Detail Information

Publications33

  1. ncbi request reprint Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer
    Naiyer A Rizvi
    Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    J Clin Oncol 20:3522-32. 2002
    ..The goals of this study were to determine the safety, toxicity, and pharmacokinetics of TAC-101, a novel synthetic retinoic acid receptor-alpha (RAR-alpha) selective retinoid, in patients with advanced cancer...
  2. pmc Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
    Naiyer A Rizvi
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 17:3500-6. 2011
    ..To determine if tumor regression following treatment with gefitinib correlates with the presence of sensitizing mutations in epidermal growth factor receptor (EGFR)...
  3. ncbi request reprint A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer
    Naiyer A Rizvi
    Developmental Therapeutics Program, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Clin Cancer Res 10:1963-70. 2004
    ....
  4. doi request reprint Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer
    Naiyer A Rizvi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:639-43. 2008
    ..We undertook this trial to determine the maximum-tolerated dose (MTD) and single-agent activity of NAB-paclitaxel administered on a weekly basis to patients with stage IV non-small-cell lung cancer (NSCLC)...
  5. pmc A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
    Paul K Paik
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lung Cancer 74:481-5. 2011
    ..Based on these data, we performed a phase II study of obatoclax mesylate plus topotecan in patients with relapsed SCLC to assess efficacy...
  6. pmc Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10022, USA
    J Clin Oncol 27:264-70. 2009
    ..However, preclinical data support the hypothesis that intermittent administration of erlotinib before or after chemotherapy may improve efficacy. We tested this hypothesis in patients with advanced NSCLC...
  7. ncbi request reprint Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 13:5150-5. 2007
    ..In these patients, we sought to assess changes in tumor metabolism and size after stopping and restarting erlotinib or gefitinib and to determine the effect of adding everolimus...
  8. doi request reprint Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer
    Katharine A Price
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York City, New York, USA
    J Thorac Oncol 5:1623-9. 2010
    ..This phase II trial assessed the efficacy of the combination of gefitinib and everolimus in patients with advanced NSCLC...
  9. doi request reprint A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations
    Gregory J Riely
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1435-7. 2011
    ..Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms. This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations...
  10. pmc A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
    Paul K Paik
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, H1011, New York, NY 10065, USA
    Cancer Chemother Pharmacol 68:1331-7. 2011
    ..We sought to determine if the incidence and severity of peripheral neuropathy could be reduced when the infusion time is lengthened to 2-h...
  11. ncbi request reprint Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer
    Daniel T Milton
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA
    Cancer 110:599-605. 2007
    ..A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC)...
  12. pmc Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib
    Melissa L Johnson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Thorac Oncol 6:1128-31. 2011
    ..The SRC inhibitor dasatinib demonstrates antitumor activity in gefitinib-resistant cells lines and xenografts. Dasatinib is tolerable for patients with advanced non-small cell lung cancer, and in combination with erlotinib...
  13. doi request reprint Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Yelena Y Janjigian
    Gastrointestinal and Thoracic Oncology Services, Division of Solid Tumor Oncology, Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Clin Cancer Res 17:2521-7. 2011
    ..To evaluate the toxicity and efficacy of cetuximab and erlotinib in patients with acquired resistance to erlotinib, we conducted this phase I/II clinical trial...
  14. pmc A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer
    Christopher G Azzoli
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Thorac Oncol 2:638-44. 2007
    ..We undertook this phase II study to measure postoperative drug delivery and toxicity of cisplatin plus docetaxel in patients with resected stage I-III non-small cell lung cancer...
  15. pmc A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development
    Binsheng Zhao
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 16:4647-53. 2010
    ....
  16. doi request reprint Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas
    Katharine Lampen-Sachar
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Lung Cancer 75:332-5. 2012
    ..To compare preoperative size of stage I and stage II lung adenocarcinoma as measured by Computed Tomography (CT) and as assessed on gross pathology specimens...
  17. doi request reprint Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer
    M Catherine Pietanza
    Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY, USA
    J Thorac Oncol 7:856-65. 2012
    ..We undertook an open-label, multi-institutional Phase II study to investigate the efficacy and safety of XL647 in treatment-naive non-small-cell lung cancer patients clinically enriched for the presence of EGFR mutations...
  18. pmc A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors
    Yelena Y Janjigian
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 1275 York Avenue, New York, NY 10065, USA
    Cancer Chemother Pharmacol 65:833-8. 2010
    ..We undertook this trial to determine the maximum-tolerated dose (MTD), toxicities and pharmacokinetic (PK) profile of SJG-136 in patients with an advanced solid tumor...
  19. ncbi request reprint A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
    Daniel T Milton
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 107:1034-41. 2006
    ..The objective of this study was to determine the tolerability and efficacy of high-dose erlotinib administered on a weekly schedule to patients with advanced nonsmall cell lung cancer (NSCLC)...
  20. pmc Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA
    J Thorac Oncol 8:346-51. 2013
    ..Metastasectomy is used in other cancers to manage oligometastatic disease. We hypothesized that local therapy is associated with improved outcomes in patients with EGFR-mutant lung cancers with acquired resistance to EGFR TKI...
  21. pmc Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis
    Stephen B Solomon
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 118, New York, NY 10021, USA
    AJR Am J Roentgenol 194:266-9. 2010
    ....
  22. doi request reprint Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
    Matthew D Hellmann
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA
    Cancer Chemother Pharmacol 72:453-61. 2013
    ..The risk of hemoptysis may be eliminated in patients with resected SQCLCs. We evaluated the safety of adjuvant bevacizumab in patients with resected SQCLCs and other lung cancers at high risk of hemoptysis...
  23. ncbi request reprint A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy
    Gregory J Riely
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lung Cancer 55:181-5. 2007
    ..TZT-1027, a derivative of dolastatin-10, has a wide spectrum of in vitro activity against cancer cell lines. We conducted a phase 2 trial of TZT-1027 in patients with previously treated non-small cell lung cancer (NSCLC)...
  24. ncbi request reprint A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors
    Matthew G Fury
    Division of Solid Tumor Oncology, Head and Neck Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Chemother Pharmacol 59:467-75. 2007
    ....
  25. doi request reprint Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers
    Jamie E Chaft
    Department of Medicine, Division of Solid Tumor Oncology, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    J Thorac Oncol 8:1084-90. 2013
    ..Bevacizumab improves survival in patients with advanced non-small-cell lung cancer (NSCLC). This phase II clinical trial assessed the effects of the addition of bevacizumab to neoadjuvant chemotherapy in resectable nonsquamous NSCLC...
  26. pmc Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer
    Yelena Y Janjigian
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
    Cancer 116:670-5. 2010
    ....
  27. pmc A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies
    Paul K Paik
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Chemother Pharmacol 66:1079-85. 2010
    ....
  28. doi request reprint Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker
    M Catherine Pietanza
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Clin Cancer Res 18:1138-45. 2012
    ..This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC)...
  29. doi request reprint A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed
    Sandra P D'Angelo
    Division of Solid Tumor Oncology, Thoracic Oncology Services, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York, USA
    J Thorac Oncol 6:624-6. 2011
    ..In the phase I and II trials, the dose-limiting toxicities of pemetrexed included neutropenia, thrombocytopenia, and fatigue. Grade 3 bilateral peripheral edema that resembled cellulitis was not commonly described...
  30. ncbi request reprint A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors
    Matthew G Fury
    Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    Cancer Chemother Pharmacol 57:671-7. 2006
    ..The aim of this phase I study was to determine the maximum-tolerated dose of pralatrexate when combined with probenecid given every 2 weeks in humans...
  31. ncbi request reprint A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma
    Irina E Popa
    Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA
    Cancer 95:1714-9. 2002
    ..The goals of the current study were to determine the safety and efficacy of a nonplatinum-containing doublet, gemcitabine and docetaxel, in the treatment of patients with chemotherapy-naive nonsmall cell lung carcinoma (NSCLC)...
  32. doi request reprint Nivolumab plus ipilimumab in advanced melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 369:122-33. 2013
    ..On the basis of their distinct immunologic mechanisms of action and supportive preclinical data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in patients with advanced melanoma...
  33. ncbi request reprint Lung cancer: computerized quantification of tumor response--initial results
    Binsheng Zhao
    Department of Medical Physics and Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 241:892-8. 2006
    ..To prospectively quantify tumor response or progression in patients with lung cancer by using thin-section computed tomography (CT) and a semiautomated algorithm to calculate tumor volume and other parameter values...

Research Grants2

  1. Correlation of EGFR Mutations and Response to Gefitinib
    Naiyer Rizvi; Fiscal Year: 2006
    ..Further characterization of tumors harboring these mutations, may have significant therapeutic implications for patients with NSCLC and change the paradigm whereby we treat patients with NSCLC. ..